1288. Bone Safety Outcomes with F/TAF vs. F/TDF for PrEP in the DISCOVER Trial

BACKGROUND: In the DISCOVER PrEP trial, emtricitabine/tenofovir alafenamide (F/TAF) was noninferior to emtricitabine/tenofovir disoproxil fumarate (F/TDF) for HIV prevention. Here we report the bone safety outcomes of F/TAF and F/TDF. METHODS: Men who have sex with men (MSM) and transgender women (T...

Descripción completa

Detalles Bibliográficos
Autores principales: Wohl, David, Ruane, Peter, Hosek, Sybil, Creticos, Catherine, Morris, Sheldon, Phoenix, John, Ramgopal, Moti, Brinson, Cynthia, Tremblay, Cecile, Carter, Christoph C, Wong, Pamela, Brainard, Diana M, McCallister, Scott, Das, Moupali, Thompson, Melanie A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809344/
http://dx.doi.org/10.1093/ofid/ofz360.1151

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809344/
http://dx.doi.org/10.1093/ofid/ofz360.1151

Ejemplares similares